NICE is unable to make a recommendation about the use in the NHS of recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals (now part of Takeda) did not provide an evidence submission. The company has advised NICE that there is a clinical study being done in the UK, so there is insufficient evidence to provide a submission for this appraisal at this stage.


If NHS organisations wish to consider recombinant human parathyroid hormone for treating hypoparathyroidism, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-3701-1

  • National Institute for Health and Care Excellence (NICE)